Agenus, Inc. (AGEN) Signs Agreement with NewVac to License, Develop and Market Agenus’ Kidney Cancer Vaccine in Russia
Agenus, Inc., a biotechnology company working to develop treatments for cancers and infectious diseases, and NewVac LLC, a Russian subsidiary of ChemRar High Tech Center, announced that NewVac has been granted an exclusive license to manufacture, market and sell Agenus' Oncophage® vaccine in the Russian Federation and CIS countries. NewVac will also pursue a development program for the vaccine in conjunction with co-adjuvant technology. Oncophage is designed to reprogram the body's immune system to target only the cancer cells, leaving the healthy tissue unaffected and limiting the depilating side effects. The drug was tested in clinical trials on nearly 800…